SI3356337T1 - Triciklične spojine vrste dibenzotiazepin za uporabo v zdravljenju motnje CDKL5 - Google Patents

Triciklične spojine vrste dibenzotiazepin za uporabo v zdravljenju motnje CDKL5

Info

Publication number
SI3356337T1
SI3356337T1 SI201630930T SI201630930T SI3356337T1 SI 3356337 T1 SI3356337 T1 SI 3356337T1 SI 201630930 T SI201630930 T SI 201630930T SI 201630930 T SI201630930 T SI 201630930T SI 3356337 T1 SI3356337 T1 SI 3356337T1
Authority
SI
Slovenia
Prior art keywords
therapy
type compounds
cdkl5 disorder
tricyclic
dibenzothiazepine type
Prior art date
Application number
SI201630930T
Other languages
English (en)
Inventor
David Cavalla
Original Assignee
Healx Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Healx Limited filed Critical Healx Limited
Publication of SI3356337T1 publication Critical patent/SI3356337T1/sl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D281/00Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02Seven-membered rings
    • C07D281/04Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/08Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D281/12Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D281/14[b, e]-condensed
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
SI201630930T 2015-09-28 2016-09-28 Triciklične spojine vrste dibenzotiazepin za uporabo v zdravljenju motnje CDKL5 SI3356337T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1517133.3A GB201517133D0 (en) 2015-09-28 2015-09-28 New pharmaceutical use
EP16777751.5A EP3356337B1 (en) 2015-09-28 2016-09-28 Tricyclic dibenzothiazepine type compounds for use in the therapy of cdkl5 disorder
PCT/GB2016/053007 WO2017055834A1 (en) 2015-09-28 2016-09-28 Tricyclic dibenzothiazepine type compounds for use in the therapy of cdkl5 disorder

Publications (1)

Publication Number Publication Date
SI3356337T1 true SI3356337T1 (sl) 2021-02-26

Family

ID=54544229

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201630930T SI3356337T1 (sl) 2015-09-28 2016-09-28 Triciklične spojine vrste dibenzotiazepin za uporabo v zdravljenju motnje CDKL5

Country Status (18)

Country Link
US (3) US20180271876A1 (sl)
EP (1) EP3356337B1 (sl)
JP (1) JP6734380B2 (sl)
CN (1) CN108368072B (sl)
AU (1) AU2016330016B2 (sl)
CA (1) CA3000070C (sl)
CY (1) CY1123564T1 (sl)
DK (1) DK3356337T3 (sl)
ES (1) ES2825326T3 (sl)
GB (1) GB201517133D0 (sl)
HR (1) HRP20201516T1 (sl)
HU (1) HUE051322T2 (sl)
LT (1) LT3356337T (sl)
PL (1) PL3356337T3 (sl)
PT (1) PT3356337T (sl)
RS (1) RS60833B1 (sl)
SI (1) SI3356337T1 (sl)
WO (1) WO2017055834A1 (sl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116377050A (zh) * 2022-12-16 2023-07-04 湖南家辉生物技术有限公司 一种发育性癫痫性脑病2型致病基因cdkl5突变位点的应用及其检测试剂和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8198268B2 (en) * 2008-10-31 2012-06-12 Janssen Biotech, Inc. Tianeptine sulfate salt forms and methods of making and using the same
GB201106520D0 (en) * 2011-04-18 2011-06-01 Numedicus Ltd Pharmaceutical compounds
CN103420937A (zh) * 2013-06-25 2013-12-04 陕西方舟制药有限公司 噻奈普汀钠的合成方法

Also Published As

Publication number Publication date
HUE051322T2 (hu) 2021-03-01
EP3356337B1 (en) 2020-06-24
GB201517133D0 (en) 2015-11-11
EP3356337A1 (en) 2018-08-08
WO2017055834A1 (en) 2017-04-06
HRP20201516T1 (hr) 2020-12-11
US20190381065A1 (en) 2019-12-19
CN108368072A (zh) 2018-08-03
US20220265676A1 (en) 2022-08-25
RS60833B1 (sr) 2020-10-30
PL3356337T3 (pl) 2021-02-08
CA3000070A1 (en) 2017-04-06
ES2825326T3 (es) 2021-05-17
LT3356337T (lt) 2020-10-12
JP6734380B2 (ja) 2020-08-05
CN108368072B (zh) 2022-02-15
AU2016330016A1 (en) 2018-05-10
US20180271876A1 (en) 2018-09-27
PT3356337T (pt) 2020-10-19
DK3356337T3 (en) 2020-09-28
CA3000070C (en) 2024-01-02
AU2016330016B2 (en) 2020-05-28
CY1123564T1 (el) 2022-03-24
JP2018534350A (ja) 2018-11-22

Similar Documents

Publication Publication Date Title
IL252135A0 (en) Triazolopyrimidine compounds and their uses
GB201520649D0 (en) Sonodynamic therapy
LT3122358T (lt) Egfr ir cmet inhibitorių deriniai, skirti vėžio gydymui
IL259996A (en) Combinations for cancer treatment
IL251371A0 (en) Cortexolone 17alpha-benzoate for use in the treatment of tumors
IL248767B (en) Trimethoxyphenyl-benzaimidazole compounds for cancer treatment
HUE044557T2 (hu) Apilimod, veserák kezelésében történõ alkalmazásra
HUE050567T2 (hu) Triciklusos heterociklusok rák kezelésére
GB2540892B (en) Pyrrolobenzodiazepine compounds
EP3440052C0 (en) COMPOUNDS FOR USE IN THE TREATMENT OF CANCER
IL249907A0 (en) Tricyclic substances containing a triazole ring
ZA201606921B (en) Use of xanthophylls for the treatment of cancers
DK3356337T3 (en) Tricyclic dibenzothiazepine type compounds for use in the therapy of cdkl5 disorder
ZA201704589B (en) Compounds for the treatment of cancer
GB201522994D0 (en) The combination of chinese medicine for treating ADHD
GB201523000D0 (en) The combination of chinese medicine for treating dysmenorrhea
GB201514416D0 (en) Meridian E-Liquid